News Breaks |
|
|
| March 15, 2013 |
| 05:37 EDT |  | NVS | Novartis says LDK378 received Breakthrough Therapy designation
Novartis announced that its investigational compound LDK378 has received Breakthrough Therapy designation by the FDA for the treatment of patients with anaplastic lymphoma kinase positive metastatic non-small cell lung cancer who had progressed during treatment with, or were intolerant to, crizotinib. According to the FDA, Breakthrough Therapy designation is intended to expedite the development and review of drugs that treat serious or life-threatening conditions if the therapy has demonstrated substantial improvement over an available therapy on at least one clinically significant endpoint. |
|
|
News For NVS From The Last 14 Days Check below for free stories on NVS the last two weeks. |
|
|
| May 20, 2013 |
| 07:29 EDT |  | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. |
|
| May 17, 2013 |
| 16:20 EDT | | NVS | Novartis drug Afinitor extended time without disease progression in women
 Subscribe for More Information |
|
| May 16, 2013 |
| 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT |  | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information |
|
| May 10, 2013 |
| 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information |
|
|
|
|
|
